Logo image of HROW

HARROW INC (HROW) Stock Fundamental Analysis

NASDAQ:HROW - US4158581094 - Common Stock

37.36 USD
-1.76 (-4.5%)
Last: 8/25/2025, 4:42:32 PM
37.41 USD
+0.05 (+0.13%)
After Hours: 8/25/2025, 4:42:32 PM
Fundamental Rating

4

HROW gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of HROW while its profitability can be described as average. HROW shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

HROW had negative earnings in the past year.
HROW had a positive operating cash flow in the past year.
HROW had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: HROW reported negative operating cash flow in multiple years.
HROW Yearly Net Income VS EBIT VS OCF VS FCFHROW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

HROW has a Return On Assets of -2.96%. This is in the better half of the industry: HROW outperforms 74.61% of its industry peers.
Looking at the Return On Equity, with a value of -20.60%, HROW is in the better half of the industry, outperforming 67.88% of the companies in the same industry.
HROW has a better Return On Invested Capital (12.04%) than 88.60% of its industry peers.
HROW had an Average Return On Invested Capital over the past 3 years of 1.25%. This is significantly below the industry average of 15.38%.
The last Return On Invested Capital (12.04%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -2.96%
ROE -20.6%
ROIC 12.04%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROW Yearly ROA, ROE, ROICHROW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

HROW's Operating Margin of 6.44% is fine compared to the rest of the industry. HROW outperforms 79.79% of its industry peers.
In the last couple of years the Operating Margin of HROW has grown nicely.
Looking at the Gross Margin, with a value of 74.56%, HROW belongs to the top of the industry, outperforming 82.38% of the companies in the same industry.
HROW's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.44%
PM (TTM) N/A
GM 74.56%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROW Yearly Profit, Operating, Gross MarginsHROW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HROW is still creating some value.
HROW has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HROW has more shares outstanding
Compared to 1 year ago, HROW has an improved debt to assets ratio.
HROW Yearly Shares OutstandingHROW Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROW Yearly Total Debt VS Total AssetsHROW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.75 indicates that HROW is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.75, HROW is doing good in the industry, outperforming 72.02% of the companies in the same industry.
HROW has a Debt/Equity ratio of 0.78. This is a neutral value indicating HROW is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.78, HROW is doing worse than 68.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 2.75
ROIC/WACC1.17
WACC10.26%
HROW Yearly LT Debt VS Equity VS FCFHROW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.62 indicates that HROW may have some problems paying its short term obligations.
The Current ratio of HROW (0.62) is worse than 91.19% of its industry peers.
HROW has a Quick Ratio of 0.62. This is a bad value and indicates that HROW is not financially healthy enough and could expect problems in meeting its short term obligations.
HROW has a worse Quick ratio (0.58) than 88.60% of its industry peers.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.58
HROW Yearly Current Assets VS Current LiabilitesHROW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

HROW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.40%, which is quite impressive.
The Revenue has grown by 47.69% in the past year. This is a very strong growth!
Measured over the past years, HROW shows a very strong growth in Revenue. The Revenue has been growing by 31.29% on average per year.
EPS 1Y (TTM)73.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.22%
Revenue 1Y (TTM)47.69%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%30.25%

3.2 Future

The Earnings Per Share is expected to grow by 72.94% on average over the next years. This is a very strong growth
Based on estimates for the next years, HROW will show a very strong growth in Revenue. The Revenue will grow by 31.80% on average per year.
EPS Next Y182.3%
EPS Next 2Y149.45%
EPS Next 3Y111.83%
EPS Next 5Y72.94%
Revenue Next Year46.72%
Revenue Next 2Y44.04%
Revenue Next 3Y39.98%
Revenue Next 5Y31.8%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
HROW Yearly Revenue VS EstimatesHROW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
HROW Yearly EPS VS EstimatesHROW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HROW. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 20.11, which indicates a rather expensive current valuation of HROW.
Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than the industry average as 75.13% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.81. HROW is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 20.11
HROW Price Earnings VS Forward Price EarningsHROW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 77.20% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 49.56
HROW Per share dataHROW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HROW's earnings are expected to grow with 111.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y149.45%
EPS Next 3Y111.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HROW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARROW INC

NASDAQ:HROW (8/25/2025, 4:42:32 PM)

After market: 37.41 +0.05 (+0.13%)

37.36

-1.76 (-4.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners57.33%
Inst Owner Change0.49%
Ins Owners15.85%
Ins Owner Change21.4%
Market Cap1.38B
Analysts85.71
Price Target61.03 (63.36%)
Short Float %14.44%
Short Ratio8.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)343.82%
Min EPS beat(2)-970.3%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)194.78%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)-25.33%
EPS beat(12)4
Avg EPS beat(12)-827.36%
EPS beat(16)5
Avg EPS beat(16)-916.47%
Revenue beat(2)0
Avg Revenue beat(2)-11.52%
Min Revenue beat(2)-17.73%
Max Revenue beat(2)-5.31%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-4.47%
Revenue beat(12)4
Avg Revenue beat(12)-3.21%
Revenue beat(16)8
Avg Revenue beat(16)-1.01%
PT rev (1m)1.85%
PT rev (3m)4.16%
EPS NQ rev (1m)20.11%
EPS NQ rev (3m)118.12%
EPS NY rev (1m)61.24%
EPS NY rev (3m)-27.55%
Revenue NQ rev (1m)-0.9%
Revenue NQ rev (3m)4.46%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)1.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.11
P/S 6.07
P/FCF N/A
P/OCF 342.41
P/B 27.84
P/tB N/A
EV/EBITDA 49.56
EPS(TTM)-0.25
EYN/A
EPS(NY)1.86
Fwd EY4.97%
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)0.11
OCFY0.29%
SpS6.15
BVpS1.34
TBVpS-3.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.96%
ROE -20.6%
ROCE 15.24%
ROIC 12.04%
ROICexc 26.8%
ROICexgc N/A
OM 6.44%
PM (TTM) N/A
GM 74.56%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexcg growth 3Y16.24%
ROICexcg growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 1.18
Cap/Depr 214.23%
Cap/Sales 16.91%
Interest Coverage 0.65
Cash Conversion 12.38%
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.58
Altman-Z 2.75
F-Score7
WACC10.26%
ROIC/WACC1.17
Cap/Depr(3y)528.86%
Cap/Depr(5y)344.75%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.22%
EPS Next Y182.3%
EPS Next 2Y149.45%
EPS Next 3Y111.83%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.69%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%30.25%
Revenue Next Year46.72%
Revenue Next 2Y44.04%
Revenue Next 3Y39.98%
Revenue Next 5Y31.8%
EBIT growth 1Y279.69%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1325.42%
EBIT Next 3Y261.99%
EBIT Next 5Y132.11%
FCF growth 1Y75.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y151.96%
OCF growth 3YN/A
OCF growth 5YN/A